Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer

CONCLUSION: Advanced EOC patients with BRCA1/2 mutations exhibited no significant difference in OS between olaparib and niraparib, indicating the need to consider individualized strategies for selecting PARP inhibitors based on adverse event profiles.PMID:38104527 | DOI:10.1016/j.ygyno.2023.11.037

Source: Gynecologic Oncology - December 17, 2023 Category: Cancer & Oncology Authors: Ji Hyun Kim Se Ik Kim Eun Young Park Eun Taeg Kim Hyesu Kim Sangeon Kim Sang-Yoon Park Myong Cheol Lim Source Type: research